What's Happening?
Forma Life Sciences has announced its launch as an independent contract development and manufacturing organization (CDMO) in Irvine, California. The company specializes in the development and manufacturing of oral solid dosage forms, including tablets
and capsules. This launch follows the acquisition of BioDuro's U.S. drug product development and manufacturing operations by BioSelective Capital Investments. Forma operates two cGMP-compliant facilities in Irvine, which together span over 100,000 square feet and include 27 GMP manufacturing suites. These facilities have the capacity to produce more than two billion tablet and capsule units annually. The company offers integrated services from early clinical development through commercial production, with expertise in spray-dried dispersion and modified-release formulation technologies.
Why It's Important?
The establishment of Forma Life Sciences as a U.S.-based CDMO is significant in the context of increasing focus on domestic pharmaceutical manufacturing and supply chain resilience. By providing a reliable platform for drug development and manufacturing, Forma supports the pharmaceutical and biotechnology industries in maintaining a steady supply of essential medications. This move aligns with broader industry trends emphasizing the importance of local manufacturing capabilities to mitigate risks associated with global supply chain disruptions. The company's capacity to handle large-scale production also positions it as a key player in meeting the growing demand for pharmaceutical products in the U.S. market.
What's Next?
As Forma Life Sciences begins operations, it is expected to strengthen its partnerships with pharmaceutical and biotechnology companies, offering them a robust platform for drug development and manufacturing. The company's leadership, with experience from BioDuro, aims to leverage its expertise to ensure disciplined execution and long-term partnerships. The focus on domestic manufacturing may also attract more clients seeking to enhance their supply chain resilience. Additionally, Forma's capabilities in advanced formulation technologies could lead to innovations in drug delivery systems, further expanding its market presence.
